ADC Contract Manufacturing Market: Tech Frontiers & Growth Trends
                     ADC Contract Manufacturing Market: 
Tech Frontiers & Growth Trends
According to Inkwood Research, the global antibody drug conjugates 
contract manufacturing market is expected to grow at a CAGR of 
12.47% over the forecast period 2024 to 2032. Antibody drug conjugate 
manufacturing is crucial in advancing cancer therapies by combining 
antibodies and cytotoxic drugs. Companies like Abzena excel in this field, 
using innovative technologies to overcome traditional challenges. 
 
Various developments and strategic alliances globally are instrumental in 
propelling precision medicine forward. Precision medicine revolutionizes 
healthcare by tailoring treatments based on individual genetic and lifestyle 
factors. Illumina and Foundation Medicine lead this field, utilizing genomic 
insights to personalize treatment strategies globally.
 
Within the Asia-Pacific, particularly in China, these efforts are magnified, with 
a strong focus on ADC development. This concerted push enhances the 
region’s influence in drug development and fosters collaborations and 
innovations.
 
Request a FREE sample of the Antibody Drug Conjugates Contract 
Manufacturing Market 
 
ADC Contract Manufacturing Market: Strategic Alliances in Cancer 
Therapies
Since the approval of the first ADC in 2000, ADC therapies have become a 
pivotal advancement in targeted cancer care. Major pharmaceutical players 
like Novartis and Pfizer, alongside startups, are actively pursuing partnerships
within the ADC space to combat cancer effectively.
 
Numerous domestic companies are now focusing on innovative ADC-based 
treatments specifically tailored for solid tumors such as breast, gastric, 
and bladder cancers. This underlines the pharmaceutical industry’s ongoing 
effort to enhance oncology drugs, with ADCs offering a promising course in 
targeted cancer treatment.
 
Concurrently, the year 2023 witnessed a significant surge in ADC-related 
deals, totaling 76 by December 26th. These deals encompassed a range of 
activities, such as licensing agreements, collaborations, and acquisitions. 
 
 Johnson & Johnson (J&J), for instance, made a significant move 
on January 8, 2024, with a $2 billionacquisition of ADC 
developer Ambrx Biopharma, bolstering its ADC pipeline. Prior to this, 
Johnson & Johnson (J&J) had finalized a significant $1.7 
billion agreement with South Korea’s LegoChem Biosciences. The 
partnership focused on the development and commercialization 
of LCB84, an exciting Trop2-directed antibody drug conjugate. 
 Another significant development is AbbVie’sproposed $10 
billion acquisition of ImmunoGen. This acquisition includes the flagship
cancer therapy ELAHERE (mirvetuximab soravtansine-gynx), an 
ADC approved for platinum-resistant ovarian cancer (PROC). 
 Eli Lilly, a major American pharmaceutical company, made two notable 
acquisitions in this field last year. In October 2023, the company 
acquired French biotech Mablink Bioscience, a pre-clinical 
biotechnology firm focused on developing next-generation ADCs using 
its PSARLinkproprietary platform. 
 Further, Daiichi Sankyoand Merck entered into a global partnership for 
three DXd ADC candidates: HER3-DXd, I-DXd, and R-DXd. This 
collaboration involves joint development and potential worldwide 
commercialization, except for Japan, where Daiichi Sankyo retains 
exclusive rights.
ADC Contract Manufacturing Market | APAC’s Position & Future Outlook 
The Asia-Pacific plays a vital role in ADC development and production, driven
by its robust biopharmaceutical industry, research infrastructure, and strategic 
collaborations. These partnerships foster innovation, accelerate drug 
discovery, and enhance manufacturing capabilities, leading to advancements 
in ADC therapies globally.
 For instance, Singapore’s Hummingbird Bioscience licensed 
its HER3-ADC, HMBD-501, to Endeavor BioMedicinesfor up to $430 
million in payments. This collaboration signifies the region’s 
contribution to the antibody drug conjugates contract manufacturing 
industry. 
 Likewise, Japanese pharmaceutical giant Takedasecured exclusive 
global rights from Innate Pharma for ADCs targeting celiac This 
acquisition showcases the region’s leadership in advancing ADC 
therapies.
Market Position: According to Inkwood Research, Asia-Pacific is anticipated
to be the leading region in the global antibody drug conjugates contract 
manufacturing market, growing at a CAGR of 13.05% over the forecasted 
period, 2024 to 2032. 
China has further emerged as a frontrunner in ADC drug development due to 
partnerships between domestic firms and major global pharmaceutical players.
This collaboration-driven approach has propelled China’s prominence in the 
ADC sector.
 
Get CUSTOMIZED market insights delivered right to your inbox! 
 
Read on to learn more about China’s strategic alliances in ADC drug 
development—
 Bristol Myers Squibb, in collaboration with SystImmune, entered an 
exclusive agreement to jointly develop BL-B01D1, an innovative 
EGFRxHER3 bispecific ADC. 
 Roche’sbillion-dollar licensed agreement with Chinese startup MediLink
Therapeutics for YL211 bolsters manufacturing capabilities in the 
region’s ADC sector.
 GlaxoSmithKlinestrengthened its oncology portfolio by 
acquiring Hansoh Pharma’s gynecologic cancer candidate (HS-20089),
demonstrating a commitment to targeted therapies.
 Eisai and China-based Bliss Biopharmaceuticalhave teamed up 
for BlissBio’s ADC candidate targeting Human Epidermal Growth 
Factor Receptor 2 (HER2).
 Shanghai-based DualityBio has gained recognition for its advanced 
ADC technology platform, which led to partnerships with major players 
such as BioNTechand BeiGene in August 2023. 
Accordingly, as per Inkwood Research, China is predicted to grow at 
a CAGR of 12.34% between 2024 to 2032 in the global antibody drug 
conjugates contract manufacturing market.
 
Precision in Practice: ADC Contract Manufacturing Industry
ADC production involves precisely conjugating a monoclonal antibody 
(mAb) with a cytotoxic drug molecule via a linker, creating a targeted 
therapeutic agent. This process requires expertise in biologics, chemistry, and 
manufacturing to ensure efficacy and safety while minimizing systemic toxicity. 
 
Accordingly, Abzena excels as a leading Contract Research Development 
and Manufacturing Organization (CRDMO), offering a wide range of 
services from drug discovery to manufacturing. Their competence ensures the 
meticulous crafting of ADCs with optimal in vivo performance and superior 
quality attributes. Abzena’s proprietary solutions maximize clinical therapy 
outcomes. Technologies like AbZelect, AbZelectPRO, 
ThioBridge, and LabZient enhance precision in interventions.
 
The success of ADCs hinges on carefully crafting elements like the antibody, 
linker, and payload. Despite the challenges posed by traditional conjugation 
methods, such as inconsistent Drug-to-Antibody Ratios (DAR) and linker 
fragility, advancements are imperative.
 
Stay up-to-date with what’s trending in the Global Antibody Drug 
Conjugates Contract Manufacturing Market
 
Abzena tackles these hurdles with ThioBridge, an advanced conjugation 
technology. ThioBridge ensures a more consistent DAR profile, preserves 
ADC integrity and improves stability and effectiveness. Its adaptability and 
design flexibility streamline ADC manufacturing, leading to cost savings and 
better results. Hence, these technologies signify a substantial leap forward in 
ADC production, amplifying enhanced stability, efficacy, and cost-
effectiveness, thereby enriching the sphere of targeted therapies.
 
Increasing global ADC demand is promoting developing growth in the ADC 
contract manufacturing market. With drug development gaining traction and 
the Asia-Pacific emerging as a key player, the market is inclined to substantial 
expansion. Collaborations, technological advancements, and a growing focus 
on personalized therapies are expected to propel the ADC contract 
manufacturing market during the forecasting years.
 
Can’t find what you’re looking for? Talk to an expert NOW!
 
FAQs:
1. How do regulatory requirements impact ADC contract 
manufacturing?
A: Regulatory requirements, such as Good Manufacturing Practices 
(GMP) and guidelines from regulatory bodies like the FDA and EMA, 
significantly influence ADC contract manufacturing. CMOs must adhere 
to these standards to ensure product safety, efficacy, consistency, and 
compliance with regulatory approvals.
2. What role does technology play in ADC contract manufacturing?
A: Technology plays a crucial role in ADC contract manufacturing by 
enabling precise conjugation processes, enhancing product quality and 
stability, improving manufacturing efficiency, and reducing production 
costs. Advanced technologies like automation, analytics, and process 
optimization tools are integral to modern ADC manufacturing facilities.